We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
TScan Therapeutics Inc | NASDAQ:TCRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.39 | -6.25% | 5.85 | 4.99 | 10.00 | 6.37 | 5.60 | 6.18 | 6,045,997 | 05:00:02 |
Poster Presentation Details:
Title: A Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies that Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell TransplantationPresenter: Monzr M. Al Malki, M.D.Abstract Number: TPS2678Session Title: Developmental Therapeutics – ImmunotherapySession Date/Time: Saturday, June 1; 9:00 a.m. - 12:00 p.m. Central TimeLocation: Hall A
Title: Initial Data from a Phase 1, First-In-Human Clinical Trial for T-Plex, a Multiplexed, Enhanced T Cell Receptor-Engineered T Cell Therapy (TCR-T) for Solid TumorsPresenter: Sajeve Thomas, M.D.Abstract Number: 2542Session Title: Developmental Therapeutics – ImmunotherapySession Date/Time: Saturday, June 1; 9:00 a.m. – 12:00 p.m. Central TimeLocation: Hall A A copy of the presentation materials will be added to the “Publications” section of the Company’s website at tscan.com once presentations have concluded.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex therapeutic TCR-Ts for patients with a variety of cancers.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP, Investor Relations857-399-9840hsavelle@tscan.com
Maghan MeyersArgot Partners212-600-1902TScan@argotpartners.com
1 Year TScan Therapeutics Chart |
1 Month TScan Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions